At a recent MIT/Sloan Management School conference on Health Systems Innovation, MIT-Sloan Professor Retzef Levi laid out problems besetting a troubled US health care system. He emphasizing the need to “sow seeds now” for a “visionary, futuristic system” to reduce future illness–and health care costs. The conference featured experts from health, science, business and industrial fields who described promising technologies and roadblocks to change. Part I in this series of blogs describes some current and potential uses of artificial intelligence and machine learning–including IBM’s Watson. Part II lays out potential solutions in health care delivery and long term care. Part III focuses on issues and efforts in behavioral and population health–and roadblocks to change.
“Convergence science has advanced across many fronts, from nanotechnology to regenerative tissue,” says Nobel Laureate Phil Sharp of MIT. “But the funding allocated for convergence research in biomedical science is small and needs to be expanded. In fact, there is no federal agency with the responsibility to fund convergence in biomedical research.”
Four Boston area Israeli collaborations receive $1.3 in funding for innovative medical and energy projects under new MA/Israel partnership.
AC Immune has entered into a second exclusive worldwide license agreement and research collaboration with Genentech,of the Roche Group, for the research, development and commercialization of AC Immune’s anti-Tau antibodies for the potential treatment of Alzheimer’s disease and other neurodegenerative diseases. The agreement is valued at $400M.
Writer-content strategist Anita Harris describes a recent panel discussion in which she, Stephen Smith of the Boston Globe and Lara Salahi of ABC News spoke to Emerson College students about careers in health communications.